Women scared to get pregnant due to overlooked disorder
If 29-year-old Marianne Barry doesn't take the contraceptive pill each day, she could have symptoms of severe anxiety or even suicidal thoughts.
Marianne has pre-menstrual dysphoric disorder (PMDD), a condition which affects as many as 8% of women, but for which the average wait time for a diagnosis is around 12 years.
Contraception remains the primary course of treatment for women living with PMDD, but for women who wish to become pregnant this poses a dilemma.
"I want to have a child, but I also want to be sane," said Marianne.
The Welsh government said it was "determined to improve the diagnosis, treatment and awareness of conditions affecting women", including PMDD.
Premenstrual disorder hits relationships - study
'My periods make me suicidal'
Marianne, a teaching assistant from Cardiff, spent eight years going back and forth to her GP before seeking a private diagnosis two years ago, when her symptoms became overwhelming.
"I would wake up in the morning and I could feel this thing bubbling up inside of me," she said.
"It was like my brain was almost hot with feelings of anger, being upset, anxiety – the anxiety was just insane."
She began to realise that her symptoms coincided with her menstrual cycle, and started to make a record of them.
"I could feel it and I'd go 'OK, well I know my period's coming.'"
Before she was prescribed the contraceptive pill, Marianne's symptoms would re-appear each month, which she said left her in a constant cycle of anxiety.
"You almost feel like you've made it up because you have this really bad low and then everything seems to start getting better again as you're coming towards that ovulation period."
According to the NHS, symptoms of PMDD are "similar to PMS, but are much more intense and can have a much greater negative impact on your everyday life".
Symptoms can include:
Headaches and joint and muscle pain
Overeating and problems sleeping
Feeling very anxious, angry, depressed or suicidal.
The exact cause of PMDD is not fully understood, but the average wait time for a diagnosis is around 12 years in Wales.
Dr Llinos Roberts, a GP, believes this is due to a lack of research.
"The treatment options are somewhat limited and I think this reflects the lack of research historically that's gone into health issues particularly affecting women," said Dr Roberts.
"The options we have are contraception, which helps reduce the symptoms of PMDD. Also you've got the options of treating the actual symptoms with CBT and antidepressants."
For Marianne, who wants children in the future, the idea of coming off her medication and her symptoms potentially returning is too daunting for her.
"There's no certainty that you're going to get pregnant, you don't know how long it's going to take. So, I want to have a child but I also want to be sane," she said.
"I'm too scared to come off my pill now."
Corinne Sinclair, 30, from Cardiff, was diagnosed with PMDD two months ago and is currently trying for a baby.
Antidepressants are her only treatment option but she has been told by doctors that if she gets pregnant, she will have to think about coming off those too.
"I think more research could be done into PMDD to give women more options that isn't just taking the contraceptive pill," said Corrine.
"It's a bit of a cop-out really and I feel they tend to do that with a lot of women's issues."
Corinne also has endometriosis, which can make conceiving a child more difficult.
She said the worry of this, and the potential return of her PMDD symptoms - which include dark thoughts and struggling to find the motivation to get out of bed - caused her a lot of stress.
"When you're trying for a baby, it's supposed to be an exciting and happy time and it is, and I'm still hopeful and looking forward to it, but there is that niggly worry at the back of your head," she said.
"After having the baby, am I going to suffer with my mental health?
"During pregnancy, am I going to be really unwell mentally?"
Dr Roberts said PMDD could be difficult to diagnose as it was often mistaken for depression or anxiety.
She advised women with suspected PMDD to keep a detailed diary of their symptoms, to keep track of when they occur and subside, and to provide that evidence to their GP.
She said there was no silver bullet for women with PMDD who wanted to have children.
"This can be very challenging for women who want to conceive but know that if they come off their contraception that's likely to exacerbate their PMDD symptoms," she said.
"If they're somebody who has significant PMDD symptoms, it's a matter of balancing the pros and cons of coming off contraception."
The Welsh government said its Women's Health Plan for Wales outlined how it was "determined to improve the diagnosis, treatment and awareness of conditions affecting women".
"Pre-menstrual dysphoric disorder (PMDD) is included as part of the menstrual health priority area within the plan," a spokesperson said.
"Funding of £3m will be used to deliver the actions in the plan."
Additional reporting by Dani Thomas.
Period-related condition causing extreme distress

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
ADHD is not really on the rise, study suggests
ADHD is not rising despite public perception that cases are increasing, a study suggests. Researchers at King's College London found little evidence to suggest that the prevalence of attention deficit hyperactivity disorder was getting worse, and said many studies suggesting an increase were of too low quality to be trusted. Dr Alex Martin, lecturer in psychology at King's, said: 'The media has been concerned about a 'surge' in ADHD diagnoses for several years. 'While assessments and help-seeking may be increasing, our study has shown significant gaps in the tracking of ADHD prevalence, resulting in a frustratingly unclear picture. 'The best data we have suggests that there has been no meaningful increase in ADHD prevalence, but most of the research is too biased to draw conclusions from.' Anecdotal reports suggest that the UK has had an unprecedented rise in the number of children and adults seeking support for ADHD, with significant backlogs of people currently awaiting assessment. The demand for ADHD diagnoses has exacerbated pressures on the NHS, with a survey by the Pensions Committee in 2023 finding that about one in four people faced delays of two years while one in 10 waited 10 years for an assessment. There were fears that the Covid pandemic and social media may have exacerbated the problem, with many more youngsters experiencing mental health issues during lockdowns. But while calls for assessments are growing, there is little evidence to suggest it was leading to a rise in the overall prevalence of the condition, the study found. The team discovered that studies suggesting ADHD rates were rising were of low quality, using self-reporting surveys, or reported symptoms from parents and teachers, rather than actual clinical diagnoses. Researchers said that the demand for assessments might be driven by increased awareness, rather than more cases. Between January and May last year, there were 25,080 media articles published on ADHD compared with 5,775 articles in the same period in 2014. The growth of the 'neurodiversity movement' may also have played a role in raising the profile of the condition and encouraging more people to seek help. Edmund Sonuga-Barke, professor of developmental psychology at King's, said: 'The neurodiversity movement, with its concentration on personal lived experience and self-compassion as the ultimate reference point for decision-making, is likely driving cultural change. 'In this regard, it's potentially increasing rates of self-referral among adolescents and adults.' In the UK, it's estimated that ADHD affects about 3-5 per cent of children and adults. The US has far higher rates, with nearly 12 per cent of youngsters diagnosed with the condition. This has led to a crackdown by the Trump administration on over-prescribing of ADHD drugs to youngsters. Prof Sonuga-Barke said US and UK rates were likely to be similar and he agreed there should be an investigation. 'I think the prevalence of ADHD is very similar in the US and the UK,' he said. 'I think there's grounds for an investigation to the impact of the prescriptive prescribing rates in the States.' A recent BBC investigation suggested that at least 196,000 adults were on NHS waiting lists for ADHD researchers said that greater awareness of the condition might also mean that young people are now using the term ADHD as 'language of distress', to signal they are struggling, even though they do not have the condition. Prof Phillip Shaw, director of the King's Maudsley Partnership for Children and Young People at King's, said: 'There's both an increased recognition and less stigma around ADHD, which means that people are increasingly coming forward for assessment. 'My hunch is that there's such a huge awareness of ADHD that it's often used as a language of distress. 'It's sometimes used, I suspect, by young people who are expressing that they are struggling, particularly at school, and need help.' This study was funded by NHS England and was conducted by the NIHR Health Protection Research Unit in Emergency Preparedness and Response. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
5 hours ago
- Yahoo
Carlisle Mum gets earlier cancer treatment thanks to 'revolutionary' blood test
A mother-of-two from Carlisle says she has been given her life back after receiving targeted cancer treatment. Rebeca Proctor, 41, from Carlisle, was diagnosed with stage 4 non-small-cell lung cancer in January. She was able to begin treatment earlier thanks to a new NHS liquid biopsy blood test, which identified a specific genetic mutation. Ms Proctor said: "When I found out I had stage 4 cancer it felt like I'd been punched in the gut, I was scared – I just thought about my children, and if I would get to see my little girl start nursery, and how I would explain my diagnosis to my children – it was just heart-breaking to think about. "But the medication has given me my life back and my kids have got their mum back. "I'm taking it day by day and for now the treatment is doing what it's meant to be doing and shrinking the tumour, and I've got my energy back. "I know I'm not going to be cured but I've come to terms with my diagnosis and the pills are stopping my cancer cells from spreading – we'll keep fighting this and dealing with what's been thrown at us." The liquid biopsy revealed she had an ALK genetic mutation, allowing her to start a targeted therapy, brigatinib. A traditional tissue biopsy confirmed the result around 10 days later. Ms Proctor is under the care of Dr Sally Hall, a consultant medical oncologist at the Northern Centre for Cancer Care in North Cumbria. The new blood test, now available across the NHS in England, detects fragments of tumour DNA in the bloodstream. It identifies genetic mutations that can guide personalised cancer treatment. NHS England recently announced that up to 15,000 patients with suspected lung cancer could benefit from the test each year. An NHS pilot found that lung cancer patients could start targeted treatment up to 16 days sooner using the liquid biopsy compared to standard tissue biopsies. The pilot also showed that some patients were able to avoid unnecessary chemotherapy and its side effects, improving their quality of life. Professor Peter Johnson, NHS national clinical director for cancer, said: "Liquid biopsies are leading us into a new era of personalised cancer care and it's fantastic that we are now able to expand the use of this revolutionary test on the NHS to help tailor treatment for thousands of patients across the country. "Cutting-edge genomic testing is helping us deliver more targeted and kinder care for patients, enabling some to avoid more intensive treatments such as further chemotherapy, which can have a huge impact." Professor Alastair Greystoke, co-clinical lead of the ctDNA pilot and honorary medical oncologist at Newcastle Hospitals, said: "This is the first ever national implementation of a 'liquid biopsy first' approach to the diagnosis and treatment of a cancer." "Not only has it led to faster and more precise treatment for patients with lung cancer, but we have also been able to show that this is a cost-effective measure for the NHS and set up the framework to evaluate this in other cancers going forward." Professor Dame Sue Hill, chief scientific officer for England, said: "This represents a real step-change in care for eligible lung and breast cancer patients on the NHS. "The liquid biopsy testing enables genomic mutations in the fragments of cancer that enter the bloodstream of these patients to be detected. "This testing is transforming care and helping clinicians match patients earlier, especially when cancer tissue may not be available, with potentially life-extending targeted therapies rapidly and with greater precision."
Yahoo
6 hours ago
- Yahoo
Pregnant women warned against using weight-loss jabs
Women using weight-loss jabs are being advised to stop if they are trying for a baby, have fallen pregnant or are breastfeeding. Drug safety experts in the UK say it's not known whether taking the medicines, such as Wegovy and Mounjaro, could harm an unborn baby. The advice already appears in patient information leaflets that come with the medicines. But there are concerns that the growing popularity of 'skinny jabs' means many women aren't using the drugs safely or getting the right advice. Natasha Major, 26, started using Mounjaro to lose weight before planning to try for her third baby in a few years' time, but was shocked six weeks later to find she was pregnant. She was taking the contraceptive pill at the time. "I have polycystic ovaries as well, so I can't get pregnant easily or quickly. So it was an even bigger shock that I had, which didn't make any sense to me," she says. She then worried she could be harming the baby or it wouldn't develop properly, so she rang her GP for advice, who told her to stop taking it. "We're over the initial shock now and really happy, just wasn't expected," she says. "The last injection I took, I found out about the pregnancy three hours later and haven't taken it since then. "I've had an early scan to make sure the pregnancy was viable and okay - baby had a little heartbeat and everything looks good," Natasha says. The UK drugs regulator, as well as doctors and pharmacists, are worried that popular GLP-1 medicines, known as Wegovy, Mounjaro, Saxenda, Victoza and Ozempic, are not being used safely. These prescription medicines, which are licensed to treat obesity (and Ozempic for type 2 diabetes), make people feel full by mimicking a hormone released after eating. Mounjaro also acts on another hormone linked to appetite and blood sugar control. They are only available on the NHS to people with a very high BMI, but such is the demand for them that many people are buying them from unregulated sellers on social media or from beauty salons, without any medical advice, as a quick fix to lose weight. How do weight loss drugs like Mounjaro and Wegovy work? Women share their bittersweet experience after taking weight-loss drugs As a precaution, the Medicines and Healthcare products Regulatory Agency (MHRA) says women should use contraception while taking GLP-1 medicines and for a certain period afterwards before trying to become pregnant - two months for Wegovy and Ozempic, and one month for Mounjaro. It also advises that those using Mounjaro and taking an oral contraceptive should also use a condom for four weeks after starting the drug, or switch to another method such as the coil or implant. Weight-loss jabs may make the contraceptive pill less likely to work in those who are overweight or obese, the MHRA says. Women should be told this information when they starting taking the jabs, but there are fears the message is not getting through. Natasha bought Mounjaro online and says she "can't remember reading anything about contraception on there". The MHRA has produced new guidance on weight-loss jabs for people taking them. It's acted now because of a very small number of reports of unintended pregnancies and complications in pregnancy made to its Yellow Card scheme, where the public can report suspected side-effects of medicines. Dr Alison Cave, chief safety officer at the MHRA, said there was evidence from animal studies "that these medicines may harm the unborn baby". "But we don't know whether we have the same effects in humans, so much more data is needed to determine that." Women of child-bearing age are usually not included in clinical trials, which is why there is a lack of safety information for them. "If you are taking this medicine and you are pregnant, you should talk to your doctor about stopping the medicine as soon as possible," she said. Sukhi Basra, vice-chairwoman of the National Pharmacy Association, said women should visit their pharmacist for advice if they are confused about when to stop using the drugs. When it comes to accessing contraception, BPAS, the British Pregnancy Advisory Service, says women in the UK "face significant challenges" when trying to access their method of choice. A lack of appointments, long waiting lists and high costs are just some of the barriers they face, BPAS said, as it called for a better plan for providing the choice women need. 'Skinny jabs' too easy to order online, GP warns Weight-loss drugs tested in head-to-head trial 'WeightWatchers set me up to fail' - Why diet industry is losing to jabs like Ozempic